PET/CT helps predict survival of patients with prostate cancer

06/26/2013 | MolecularImaging.net

Metabolic imaging using 18F-FDG-PET/CT helps predict the overall survival of patients with castrate-resistant metastatic prostate cancer, according to a study published in The Journal of Nuclear Medicine. Data provided by the imaging method "may be useful in assessing the comparative effectiveness of various conventional and emerging treatment strategies," researchers said.

View Full Article in:

MolecularImaging.net

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ